Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameCancer vaccine (BN ImmunoTherapeutics/National Cancer Institute)
Drug Alias NameCEA-MUC-1/TRICOMPANVAC-V/FPANVAC-VFinalimarev + falimarevPanvac +[9] 
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsImmunostimulantsAnti-MUC1
TargetsMucin-1Carcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTherion Biologics
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesTherion Biologics CoGeorgetown UniversityBavarian Nordic A/S
Active IndicationsProstatic NeoplasmsPancreatic NeoplasmsColorectal Neoplasms +[5] 
Inactive IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[11] 

Other Information

ATC CodeN/A
Related LinksN/A